FDA Inspection 1040193 — Oklahoma Blood Institute
The FDA completed an inspection of Oklahoma Blood Institute on Dec 7, 2017 in Tulsa, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 7, 2017
- Fiscal Year
- 2018
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Tulsa, OK (United States)